相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetics of antiretrovirals
Valerio Tozzi
ANTIVIRAL RESEARCH (2010)
P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile
Latha G. Nair et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Abacavir and cardiovascular risk
Georg M. N. Behrens et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2010)
Boceprevir, an NS3 Protease Inhibitor of HCV
Kenneth Berman et al.
CLINICS IN LIVER DISEASE (2009)
An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C
Raf Crabbe et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Randomized Trial Comparing Pegylated Interferon alpha-2b Versus Pegylated Interferon alpha-2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus Patients
Montserrat Laguno et al.
HEPATOLOGY (2009)
The Cyclophilin Inhibitor Debio 025 Combined with PEG IFNα2a Significantly Reduces Viral Load in Treatment-Naive Hepatitis C Patients
Robert Flisiak et al.
HEPATOLOGY (2009)
A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C: ViSER1 Results
Yves Benhamou et al.
HEPATOLOGY (2009)
Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts
C. Torti et al.
INFECTION (2009)
Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - An extended haplotype of genetic variants increases risk in indinavir treatment
Tim O. Lankisch et al.
JOURNAL OF HEPATOLOGY (2009)
Ribavirin: Current role in the optimal clinical management of chronic hepatitis C
K. Rajender Reddy et al.
JOURNAL OF HEPATOLOGY (2009)
Toward Second Generation Hepatitis C Virus NS3 Serine Protease Inhibitors: Discovery of Novel P4 Modified Analogues with Improved Potency and Pharmacokinetic Profile
Ashok Arasappan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
Sonia Rodriguez-Novoa et al.
AIDS (2008)
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
Roger G. Ptak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C
Stefan Zeuzein et al.
HEPATOLOGY (2008)
The cyclophilin inhibitor debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
Robert Flisiak et al.
HEPATOLOGY (2008)
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
Jose A. Mira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
Paul J. Pockros et al.
JOURNAL OF HEPATOLOGY (2007)
Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients
B. Ramos et al.
JOURNAL OF VIRAL HEPATITIS (2007)
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
F Bani-Sadr et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care
MMR Maat et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2004)
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus
C Martinez-Sierra et al.
CLINICAL INFECTIOUS DISEASES (2003)
Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients
MLM Ramírez et al.
REVISTA CLINICA ESPANOLA (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
I Bica et al.
CLINICAL INFECTIOUS DISEASES (2001)
分享论文
